Viking Therapeutics' diabetes stock, VKTX, enters late-stage trial early for its weight loss injection VK2735.

Viking Therapeutics' diabetes stock, VKTX, is considered the best investment due to its weight loss injection, VK2735, entering a late-stage trial ahead of schedule. The global diabetes care market is expected to grow rapidly, with the continuous glucose monitor (CGM) market reaching $33.4B by 2030 and glucagon-like peptide-1 (GLP-1) market reaching $100B. Hedge funds view Pfizer, Insulet, and Merck as promising investments in the growing diabetes care market, with advanced diabetes care products including insulin pumps, pens, and CGMs estimated to reach $33.4B by 2030. As AI integrates into CGM technology, the demand for diabetes and weight loss treatments increases, making these stocks attractive investment opportunities.

August 17, 2024
17 Articles

Further Reading